BioNexus Gene Lab Corp Cash Flow Statement
BGLC|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$2M
FY2025
Free Cash Flow
-$2M
FY2025
Capital Expenditures
$36,971
Cash used for long-term assets
Dividends Paid
N/A
FY2025
BioNexus Gene Lab Corp used $2M in operating cash flow and negative free cash flow of $2M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -34.6% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$3.0M | -$1.6M | -$2.6M | -$356.0K | $751.6K | $1.1M | -$246.5K |
| Depreciation & Amortization | - | - | - | - | - | - | $41.7K |
| Operating Cash Flow | -$1.8M | -$2.1M | -$1.8M | $551.8K | $9.2K | $552.7K | -$217.3K |
| Capital Expenditures | $37.0K | $227.0K | $149.4K | $0 | $3.2K | $421.6K | $12.8K |
| Free Cash Flow | -$1.9M | -$2.3M | -$2.0M | $551.8K | $6.0K | $131.1K | -$230.1K |
| FCF Margin | -25.3% | -24.4% | -20.2% | 5.1% | 0.0% | 1.1% | -181.2% |